A comprehensive new review published in The Lancet affirms that currently approved mRNA vaccines are safe and highly ...

The continued evolution of SARS-CoV-2 variants that evade immunity highlights a need to develop vaccines that elicit variant-specific antibodies and neutralize emerging strains. However, immune ...

The race to tame Covid-19 has resulted in a wealth of research, new vaccines and promising treatments that hold out the ...

Alnylam Pharmaceuticals’ ALNY primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the ...

In some of Asia’s Covid-19 hotspots, powerful and wealthier citizens are nabbing booster shots even as most people remain ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across ...

The analysis included 14,019 cases of the Delta variant – 166 of whom were hospitalised – between April 12 and June 4.

According to the Centers for Disease Control and Prevention's COVID ⁠dashboard, new data is currently unavailable due to low sequencing submissions. The most recent update, now ...

The FDA’s outside vaccine advisers overwhelmingly recommended Thursday that the agency direct manufacturers to base their 2026-2027 formulas on the dominant XFG Covid variant.

An FDA advisory panel voted 8-0, with one abstention, to recommend updating COVID-19 vaccines for the 2026-27 season to target the dominant XFG variant, despite concerns from some members about ...

Pfizer will receive an exclusive global license for four programs. (cybrain/Getty Images) Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers ...